$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter

Equities analysts predict that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will post sales of $14.56 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Amicus Therapeutics’ earnings, with the lowest sales estimate coming in at $13.63 million and the highest estimate coming in at $15.73 million. Amicus Therapeutics posted sales of $2.83 million during the same quarter last year, which suggests a positive year-over-year growth rate of 414.5%. The company is scheduled to report its next quarterly earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Amicus Therapeutics will report full-year sales of $14.56 million for the current financial year, with estimates ranging from $32.90 million to $37.13 million. For the next financial year, analysts expect that the business will post sales of $0.00 per share. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Amicus Therapeutics.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s quarterly revenue was up 419.0% compared to the same quarter last year. During the same period last year, the business earned ($0.33) EPS.

A number of analysts have issued reports on FOLD shares. Robert W. Baird reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a report on Monday, September 25th. Zacks Investment Research lowered Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Bank of America raised their target price on Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $18.31.

Amicus Therapeutics (NASDAQ FOLD) traded up $0.37 on Friday, reaching $16.15. The company’s stock had a trading volume of 2,502,700 shares, compared to its average volume of 2,948,783. The firm has a market cap of $2,630.00, a price-to-earnings ratio of -8.83 and a beta of 1.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a 12-month low of $5.07 and a 12-month high of $16.60.

In related news, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the transaction, the insider now owns 69,184 shares in the company, valued at approximately $940,210.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John F. Crowley sold 5,920 shares of the firm’s stock in a transaction that occurred on Saturday, December 29th. The stock was sold at an average price of $14.75, for a total value of $87,320.00. Following the transaction, the chief executive officer now owns 341,051 shares of the company’s stock, valued at approximately $5,030,502.25. The disclosure for this sale can be found here. Insiders have sold a total of 197,890 shares of company stock worth $2,767,181 in the last three months. 3.40% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. Alliancebernstein L.P. lifted its position in shares of Amicus Therapeutics by 16.3% during the 2nd quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock worth $2,073,000 after buying an additional 28,800 shares during the period. Bank of Nova Scotia bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $1,944,000. American International Group Inc. lifted its position in shares of Amicus Therapeutics by 23.1% during the 3rd quarter. American International Group Inc. now owns 109,628 shares of the biopharmaceutical company’s stock worth $1,653,000 after buying an additional 20,597 shares during the period. Redmile Group LLC lifted its position in shares of Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after buying an additional 668,080 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Amicus Therapeutics by 5.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after buying an additional 430,486 shares during the period.

TRADEMARK VIOLATION WARNING: “$14.56 Million in Sales Expected for Amicus Therapeutics, Inc. (FOLD) This Quarter” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/19/14-56-million-in-sales-expected-for-amicus-therapeutics-inc-fold-this-quarter-3.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Get a free copy of the Zacks research report on Amicus Therapeutics (FOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply